{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intermediate-risk+Myelodysplastic+Syndrome&page=2",
    "query": {
      "condition": "Intermediate-risk Myelodysplastic Syndrome",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 48,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intermediate-risk+Myelodysplastic+Syndrome&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intermediate-risk+Myelodysplastic+Syndrome&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T04:14:23.925Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01772420",
      "title": "Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Myelodysplastic Syndrome",
        "Anemia",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Eltrombopag Olamine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2012-10",
      "completion_date": "2020-07-09",
      "has_results": true,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas • The Bronx, New York",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01772420"
    },
    {
      "nct_id": "NCT01624805",
      "title": "Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aplastic Anemia",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Previously Treated Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2012-06-25",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624805"
    },
    {
      "nct_id": "NCT02943668",
      "title": "Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Deferasirox",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2017-03-02",
      "completion_date": "2018-12-17",
      "has_results": true,
      "last_update_posted_date": "2020-07-01",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02943668"
    },
    {
      "nct_id": "NCT03516591",
      "title": "A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "AMV564 14-Day CIV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amphivena Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-06-22",
      "completion_date": "2020-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Tampa, Florida • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03516591"
    },
    {
      "nct_id": "NCT03263091",
      "title": "Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Roxadustat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyntra Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2018-01-29",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-08-01",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 30,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Burbank, California + 25 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03263091"
    },
    {
      "nct_id": "NCT01003678",
      "title": "Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2009-10",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01003678"
    },
    {
      "nct_id": "NCT07422480",
      "title": "A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Elritercept",
          "type": "DRUG"
        },
        {
          "name": "Epoetin Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2026-05-21",
      "completion_date": "2033-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 31,
      "location_summary": "Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07422480"
    },
    {
      "nct_id": "NCT04623996",
      "title": "A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anemia in Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "TP-0184",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-12-28",
      "completion_date": "2021-04-27",
      "has_results": true,
      "last_update_posted_date": "2023-11-09",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 3,
      "location_summary": "Plantation, Florida • The Bronx, New York • Austin, Texas",
      "locations": [
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04623996"
    },
    {
      "nct_id": "NCT03946670",
      "title": "A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "MBG453",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Hypomethylating agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 127,
      "start_date": "2019-06-04",
      "completion_date": "2024-07-15",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 7,
      "location_summary": "Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03946670"
    },
    {
      "nct_id": "NCT04419649",
      "title": "A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Cytopenia"
      ],
      "interventions": [
        {
          "name": "Elritercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2020-08-19",
      "completion_date": "2031-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-06T04:14:23.925Z",
      "location_count": 11,
      "location_summary": "Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04419649"
    }
  ]
}